Fresenius Biotech North America, Inc.
Fresenius Biotech, a subsidiary of the Fresenius Group, is a biotechnology company focused on development and commercialization of immunoactive therapeutics. Our products leverage the biologic reaction of the bodies own immune system to treat the underlying primary disease. Our therapeutic focus is Oncology and Transplant.
Our commercial products are Removab, an EMEA approved trifunctional antibody that enhances the hosts immune response to cancer cells and ATG-Fresenius S, an anti-T lymphocyte-globulin approved in over 50 countries to improve outcomes in solid organ and stem cell transplantation. Both products are in late stage development for entry to the US.
Fresenius Biotech North America is focused on maximizing the value of Fresenius Biotech’s products in North America through strategic clinical and commercial development